Relmada Therapeutics, Inc. RLMD Retained Earnings
Retained Earnings at other companies
Other financials
Where this comes from
Reported directly by Relmada Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RetainedEarningsAccumulatedDeficit.
The official record: Relmada Therapeutics, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Relmada Therapeutics, Inc.'s retained earnings.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Relmada Therapeutics, Inc.'s retained earnings?
- Relmada Therapeutics, Inc. (RLMD) reported retained earnings of -$717.32M in Q1 2026.
- How has Relmada Therapeutics, Inc.'s retained earnings changed year-over-year?
- Relmada Therapeutics, Inc.'s retained earnings decreased by 8.9% year-over-year, from -$658.44M to -$717.32M.
- What is the long-term trend for Relmada Therapeutics, Inc.'s retained earnings?
- Over 5 years (2020 to 2025), Relmada Therapeutics, Inc.'s retained earnings has grown at a 31.2% compound annual growth rate (CAGR), from -$179.32M to -$698.27M.
- What does retained earnings mean?
- Cumulative net income earned since inception minus all dividends paid — the total profits reinvested in the business over its lifetime.